D
Donald P. Lawrence
Researcher at Harvard University
Publications - 147
Citations - 21925
Donald P. Lawrence is an academic researcher from Harvard University. The author has contributed to research in topics: Melanoma & Trametinib. The author has an hindex of 48, co-authored 136 publications receiving 18034 citations. Previous affiliations of Donald P. Lawrence include Brigham and Women's Hospital & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst,Jean-Charles Soria,Marcin Kowanetz,Gregg Fine,Omid Hamid,Michael S. Gordon,J. A. Sosman,David F. McDermott,John D. Powderly,Scott N. Gettinger,Holbrook E Kohrt,Leora Horn,Donald P. Lawrence,Sandra Rost,Maya Leabman,Yuanyuan Xiao,Ahmad Mokatrin,Hartmut Koeppen,Priti S. Hegde,Ira Mellman,Daniel S. Chen,F. Stephen Hodi +21 more
TL;DR: Evaluated data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment, as well as across multiple cancer types.
Journal ArticleDOI
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian,Mario Sznol,David F. McDermott,Harriet M. Kluger,Richard D. Carvajal,William H. Sharfman,Julie R. Brahmer,Donald P. Lawrence,Michael B. Atkins,John D. Powderly,Philip D. Leming,Evan J. Lipson,Igor Puzanov,David Smith,Janis M. Taube,Jon M. Wigginton,Georgia Kollia,Ashok Kumar Gupta,Drew M. Pardoll,Jeffrey A. Sosman,F. Stephen Hodi +20 more
TL;DR: Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations, and responses were durable and persisted after drug discontinuation.
Journal ArticleDOI
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman,Kevin B. Kim,Lynn M. Schuchter,Rene Gonzalez,Anna C. Pavlick,Jeffrey S. Weber,Grant A. McArthur,Thomas E. Hutson,Stergios J. Moschos,Keith T. Flaherty,Peter Hersey,Richard F. Kefford,Donald P. Lawrence,Igor Puzanov,Karl D. Lewis,Ravi K. Amaravadi,Bartosz Chmielowski,H. Jeffrey Lawrence,Yu Shyr,Fei Ye,Jiang Li,K. B. Nolop,Richard J. Lee,Andrew K. Joe,Antoni Ribas +24 more
TL;DR: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma, and the median overall survival in this study with a long follow-up was approximately 16 months.
Journal ArticleDOI
Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial
Kim Margolin,Marc S. Ernstoff,Omid Hamid,Donald P. Lawrence,David F. McDermott,Igor Puzanov,Jedd D. Wolchok,Joseph I. Clark,Mario Sznol,Theodore F. Logan,Jon M. Richards,Tracy Michener,Agnes Balogh,Kevin N. Heller,F. Stephen Hodi +14 more
TL;DR: Ipilimumab has activity in some patients with advanced melanoma and brain metastases, particularly when metastases are small and asymptomatic, and the drug has no unexpected toxic effects in this population.
Journal ArticleDOI
Myocarditis in patients treated with immune checkpoint inhibitors
Syed S. Mahmood,Michael G. Fradley,Justine V. Cohen,Anju Nohria,Kerry L. Reynolds,Lucie Heinzerling,Ryan J. Sullivan,Rongras Damrongwatanasuk,Carol L. Chen,Dipti Gupta,Michael C. Kirchberger,Magid Awadalla,Malek Z.O. Hassan,Javid Moslehi,Sachin P. Shah,Sarju Ganatra,Paaladinesh Thavendiranathan,Donald P. Lawrence,John D. Groarke,Tomas G. Neilan +19 more
TL;DR: Myocarditis after ICI therapy may be more common than appreciated, occurs early after starting treatment, has a malignant course, and responds to higher steroid doses.